{"parse":{"title":"Supplementary protection certificate","pageid":2202344,"revid":844871433,"text":{"*":"<div class=\"mw-parser-output\"><p class=\"mw-empty-elt\">\n\n</p>\n<table class=\"vertical-navbox nowraplinks plainlist\" style=\"float:right;clear:right;width:22.0em;margin:0 0 1.0em 1.0em;background:#f9f9f9;border:1px solid #aaa;padding:0.2em;border-spacing:0.4em 0;text-align:center;line-height:1.4em;font-size:88%\"><tbody><tr><th style=\"padding:0.2em 0.4em 0.2em;font-size:145%;line-height:1.2em\"><a href=\"/wiki/Intellectual_property\" title=\"Intellectual property\">Intellectual property</a></th></tr><tr><th style=\"padding:0.1em;background:#aaddff; color:#000;\">\nPrimary rights</th></tr><tr><td style=\"padding:0 0.1em 0.4em\">\n<div class=\"hlist\">\n<ul><li><a href=\"/wiki/Intellectual_rights\" title=\"Intellectual rights\">Intellectual rights</a></li>\n<li><a href=\"/wiki/Copyright\" title=\"Copyright\">Copyright</a></li>\n<li><a href=\"/wiki/Patent\" title=\"Patent\">Patent</a></li>\n<li><a href=\"/wiki/Trademark\" title=\"Trademark\">Trademark</a></li>\n<li><a href=\"/wiki/Trade_dress\" title=\"Trade dress\">Trade dress</a></li>\n<li><a href=\"/wiki/Trade_secret\" title=\"Trade secret\">Trade secret</a></li>\n<li><a href=\"/wiki/Geographical_indication\" title=\"Geographical indication\">Geographical indication</a></li></ul>\n</div></td>\n</tr><tr><th style=\"padding:0.1em;background:#aaddff; color:#000;\">\n<i><a href=\"/wiki/Sui_generis\" title=\"Sui generis\">Sui generis</a></i> rights</th></tr><tr><td style=\"padding:0 0.1em 0.4em\">\n<div class=\"hlist\">\n<ul><li><a href=\"/wiki/Authors%27_rights\" title=\"Authors&#39; rights\">Authors' rights</a></li>\n<li><a href=\"/wiki/Database_right\" class=\"mw-redirect\" title=\"Database right\">Database right</a></li>\n<li><a href=\"/wiki/Indigenous_intellectual_property\" title=\"Indigenous intellectual property\">Indigenous intellectual property</a></li>\n<li><a href=\"/wiki/Industrial_design_right\" title=\"Industrial design right\">Industrial design right</a></li>\n<li><a href=\"/wiki/Integrated_circuit_layout_design_protection\" title=\"Integrated circuit layout design protection\">Integrated circuit layout design protection</a></li>\n<li><a href=\"/wiki/Moral_rights\" title=\"Moral rights\">Moral rights</a></li>\n<li><a href=\"/wiki/Plant_breeders%27_rights\" title=\"Plant breeders&#39; rights\">Plant breeders' rights</a></li>\n<li><a href=\"/wiki/Related_rights\" title=\"Related rights\">Related rights</a></li>\n<li><a class=\"mw-selflink selflink\">Supplementary protection certificate</a></li>\n<li><a href=\"/wiki/Utility_model\" title=\"Utility model\">Utility model</a></li></ul>\n</div></td>\n</tr><tr><th style=\"padding:0.1em;background:#aaddff; color:#000;\">\nRelated topics</th></tr><tr><td style=\"padding:0 0.1em 0.4em\">\n<div class=\"hlist\">\n<ul><li><a href=\"/wiki/Abandonware\" title=\"Abandonware\">Abandonware</a></li>\n<li><a href=\"/wiki/Anti-copyright\" class=\"mw-redirect\" title=\"Anti-copyright\">Anti-copyright</a></li>\n<li><a href=\"/wiki/Bioprospecting\" title=\"Bioprospecting\">Bioprospecting</a></li>\n<li><a href=\"/wiki/Cultural_appropriation\" title=\"Cultural appropriation\">Cultural appropriation</a></li>\n<li><a href=\"/wiki/Limitations_and_exceptions_to_copyright\" title=\"Limitations and exceptions to copyright\">Limitations and exceptions to copyright</a>\n<ul><li><a href=\"/wiki/Fair_dealing\" title=\"Fair dealing\">Fair dealing</a></li>\n<li><a href=\"/wiki/Fair_use\" title=\"Fair use\">Fair use</a></li>\n<li><a href=\"/wiki/Paraphrasing_of_copyrighted_material\" title=\"Paraphrasing of copyrighted material\">Paraphrasing</a></li>\n<li><a href=\"/wiki/Right_to_quote\" title=\"Right to quote\">Right to quote</a></li></ul></li>\n<li><a href=\"/wiki/Orphan_works\" class=\"mw-redirect\" title=\"Orphan works\">Orphan works</a></li>\n<li><a href=\"/wiki/Patent_troll\" title=\"Patent troll\">Patent troll</a></li>\n<li><a href=\"/wiki/Public_domain\" title=\"Public domain\">Public domain</a></li></ul>\n</div>\n<ul><li><a href=\"/wiki/Outline_of_intellectual_property\" title=\"Outline of intellectual property\">Outline of intellectual property</a> (<a href=\"/wiki/Outline_of_patents\" title=\"Outline of patents\">Outline of patents</a>)</li></ul>\n<hr />\n<i>Higher category:</i> <a href=\"/wiki/Property\" title=\"Property\">Property</a> and <a href=\"/wiki/Property_law\" title=\"Property law\">Property law</a></td>\n</tr><tr><td style=\"text-align:right;font-size:115%\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Intellectual_property\" title=\"Template:Intellectual property\"><abbr title=\"View this template\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Intellectual_property\" title=\"Template talk:Intellectual property\"><abbr title=\"Discuss this template\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Intellectual_property&amp;action=edit\"><abbr title=\"Edit this template\">e</abbr></a></li></ul></div></td></tr></tbody></table>\n<table class=\"vertical-navbox nowraplinks plainlist\" style=\"float:right;clear:right;width:22.0em;margin:0 0 1.0em 1.0em;background:#f9f9f9;border:1px solid #aaa;padding:0.2em;border-spacing:0.4em 0;text-align:center;line-height:1.4em;font-size:88%;width:auto;\"><tbody><tr><th style=\"padding:0.2em 0.4em 0.2em;font-size:145%;line-height:1.2em\"><a href=\"/wiki/European_patent_law\" title=\"European patent law\">European patent law</a></th></tr><tr><th style=\"padding:0.1em;line-height:1.2em; background:#aaddff; color:#000;\">\n<a href=\"/wiki/European_Patent_Organisation\" title=\"European Patent Organisation\">European Patent<br />Organisation</a></th></tr><tr><td style=\"padding:0 0.1em 0.4em\">\n<ul><li><a href=\"/wiki/European_Patent_Convention\" title=\"European Patent Convention\">European Patent Convention</a></li>\n<li><a href=\"/wiki/European_Patent_Office\" title=\"European Patent Office\">European Patent Office</a></li></ul></td>\n</tr><tr><th style=\"padding:0.1em;line-height:1.2em; background:#aaddff; color:#000;\">\n<a href=\"/wiki/Patent_law_of_the_European_Union\" title=\"Patent law of the European Union\">European Union</a></th></tr><tr><td style=\"padding:0 0.1em 0.4em\">\n<ul><li><a href=\"/wiki/Directive_on_the_patentability_of_biotechnological_inventions\" class=\"mw-redirect\" title=\"Directive on the patentability of biotechnological inventions\">Biotech directive</a></li>\n<li><a class=\"mw-selflink selflink\">Supplementary protection certificate</a></li>\n<li><a href=\"/wiki/Unitary_patent\" title=\"Unitary patent\">Unitary patent</a></li>\n<li><a href=\"/wiki/Unified_Patent_Court\" title=\"Unified Patent Court\">Unified Patent Court</a></li></ul></td>\n</tr><tr><th style=\"padding:0.1em;line-height:1.2em; background:#aaddff; color:#000;\">\n<a href=\"/wiki/Eurasian_Patent_Organization\" title=\"Eurasian Patent Organization\">Eurasian Patent<br />Organization</a></th></tr><tr><td style=\"padding:0 0.1em 0.4em\">\n<ul><li><a href=\"/wiki/Eurasian_Patent_Convention\" title=\"Eurasian Patent Convention\">Eurasian Patent Convention</a></li>\n<li><a href=\"/wiki/Eurasian_Patent_Office\" class=\"mw-redirect\" title=\"Eurasian Patent Office\">Eurasian Patent Office</a></li></ul></td>\n</tr><tr><th style=\"padding:0.1em;line-height:1.2em; background:#aaddff; color:#000;\">\nCentralization<br />and harmonization</th></tr><tr><td style=\"padding:0 0.1em 0.4em\">\n<ul><li><a href=\"/wiki/Brussels_Regime\" title=\"Brussels Regime\">Brussels Regime</a></li>\n<li><a href=\"/wiki/Cross-border_injunction\" title=\"Cross-border injunction\">Cross-border injunction</a></li>\n<li><a href=\"/wiki/London_Agreement_(2000)\" title=\"London Agreement (2000)\">London Agreement</a></li></ul></td>\n</tr><tr><th style=\"padding:0.1em;line-height:1.2em; background:#aaddff; color:#000;\">\nHistorical proposals</th></tr><tr><td style=\"padding:0 0.1em 0.4em\">\n<ul><li><div style=\"padding:0.2em 0.4em; line-height:1.2em; line-height:1.1em;\"><a href=\"/wiki/European_Patent_Litigation_Agreement\" title=\"European Patent Litigation Agreement\">European Patent Litigation<br />Agreement (EPLA)</a></div></li></ul></td>\n</tr><tr><td style=\"text-align:right;font-size:115%\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:European_patent_law\" title=\"Template:European patent law\"><abbr title=\"View this template\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:European_patent_law\" title=\"Template talk:European patent law\"><abbr title=\"Discuss this template\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:European_patent_law&amp;action=edit\"><abbr title=\"Edit this template\">e</abbr></a></li></ul></div></td></tr></tbody></table>\n<p>In the <a href=\"/wiki/European_Economic_Area\" title=\"European Economic Area\">European Economic Area</a> (<a href=\"/wiki/European_Union\" title=\"European Union\">European Union</a> member countries, Iceland, Liechtenstein and Norway), a <b>supplementary protection certificate</b> (<b>SPC</b>) is a <i><a href=\"/wiki/Sui_generis\" title=\"Sui generis\">sui generis</a></i> intellectual property (IP) right that extends the duration of certain rights associated with a patent. It enters into force after expiry of a patent upon which it is based. This type of right is available for various regulated, biologically active agents, namely human or veterinary medicaments and plant protection products (e.g. <a href=\"/wiki/Insecticide\" title=\"Insecticide\">insecticides</a>, and <a href=\"/wiki/Herbicide\" title=\"Herbicide\">herbicides</a>). Supplementary protection certificates were introduced to encourage innovation by compensating for the long time needed to obtain regulatory approval of these products (i.e. authorisation to put these products on the market).<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup>\n</p><p>A supplementary protection certificate comes into force only after the corresponding general patent expires. It normally has a maximum lifetime of 5 years. The duration of the SPC can, however, be extended to 5.5 years when the SPC relates to a human medicinal product for which data from clinical trials conducted in accordance with an agreed Paediatric Investigation Plan (PIP) have been submitted (as set out in Article 36 of Regulation (EC) No 1901/2006<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>).\n</p><p>The total combined duration of market exclusivity of a general patent and SPC cannot normally exceed 15 years. However, the reward of a 6-month SPC extension for the submission of data from an agreed PIP can extend this combined duration to 15.5 years.\n</p><p>SPCs extend the monopoly period for a \"product\" (active ingredient or a combination of active ingredients) that is protected by a patent. For many SPC applications, there is no controversy about the definition of the \"product\" or whether it is protected by the patent upon which the SPC application was based. However, there are other SPC applications (particularly for medicinal products containing multiple active ingredients) where there may not be clear answers to questions such as what is a permissible definition of a \"product\", and what test should be applied for determining whether a patent protects that \"product\".\n</p><p>Supplementary protection certificates in the European Union are based primarily upon two <a href=\"/wiki/European_Union_regulation\" class=\"mw-redirect\" title=\"European Union regulation\">regulations</a>. Although all countries in the EU are required to provide supplementary protection certificates, no unified cross-recognition exist. Applications must be filed and approved on a country-by-country basis.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Scope\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Scope</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Legal_basis\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Legal basis</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Determination_of_term\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Determination of term</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Paediatric_extension\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">Paediatric extension</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Case_law\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Case law</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Statistics\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Statistics</span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#See_also\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#References\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#External_links\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">External links</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-10\"><a href=\"#Search\"><span class=\"tocnumber\">8.1</span> <span class=\"toctext\">Search</span></a></li>\n</ul>\n</li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Scope\">Scope</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Supplementary_protection_certificate&amp;action=edit&amp;section=1\" title=\"Edit section: Scope\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>According to Article 4 of <a href=\"/wiki/Council_of_the_European_Union\" title=\"Council of the European Union\">Council</a> Regulation (<a href=\"/wiki/European_Community\" class=\"mw-redirect\" title=\"European Community\">EEC</a>) No 1768/92, the scope of an SPC extends \"<i>only to the product covered by the authorization to place the corresponding medicinal product on the market and for any use of the product as a medicinal product that has been authorized before the expiry of the certificate</i>\".\n</p><p>The European Court of Justice has decided, however, that the scope of an SPC is sometimes capable of encompassing more than just the single form of the active ingredient that is included in the medicinal product authorised for sale. Thus, in case C-392/97,<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup> the European Court of Justice held that:\n\"<i>where an active ingredient in the form of a salt is referred to in the marketing authorisation concerned and is protected by a basic patent in force, the certificate is capable of covering the active ingredient as such and also its various derived forms such as salts and esters, as medicinal products, in so far as they are covered by the protection of the basic patent</i>\".\n</p>\n<h2><span class=\"mw-headline\" id=\"Legal_basis\">Legal basis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Supplementary_protection_certificate&amp;action=edit&amp;section=2\" title=\"Edit section: Legal basis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Supplementary protection certificates in the European Union were based primarily upon two regulations:\n</p>\n<ul><li><a href=\"/wiki/Council_of_the_European_Union\" title=\"Council of the European Union\">Council</a> Regulation (<a href=\"/wiki/European_Community\" class=\"mw-redirect\" title=\"European Community\">EEC</a>) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup> which entered into force on 2 January 1993. This has been cancelled by the below specified recodified regulation No <a rel=\"nofollow\" class=\"external text\" href=\"http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:152:0001:0010:en:PDF\">469/2009</a> with effect from May 2009</li>\n<li>Regulation (<a href=\"/wiki/European_Community\" class=\"mw-redirect\" title=\"European Community\">EC</a>) No 1610/96 of the <a href=\"/wiki/European_Parliament\" title=\"European Parliament\">European Parliament</a> and of the Council of 23 July 1996 concerning the creation of a supplementary protection certificate for plant protection products<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup> which entered into force on 8 February 1997</li></ul>\n<p>The above Regulations have now been codified under the following regulation:\n</p>\n<ul><li>Regulation (<a href=\"/wiki/European_Community\" class=\"mw-redirect\" title=\"European Community\">EC</a>) No <a rel=\"nofollow\" class=\"external text\" href=\"http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:152:0001:0010:en:PDF\">469/2009</a> of the <a href=\"/wiki/European_Parliament\" title=\"European Parliament\">European Parliament</a> and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version)<sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup></li></ul>\n<p>Supplementary protection certificates may come into life at the expiry of a national or European patent. However, the <a href=\"/wiki/European_Patent_Convention\" title=\"European Patent Convention\">European Patent Convention</a> (EPC) needed to be modified to allow such \"extension\" of the term of European patent. Article 63 of the EPC was modified on 17 December 1991 to specify to, although European patents have a <a href=\"/wiki/Term_of_patent\" title=\"Term of patent\">term</a> of 20 years as from the date of filing of the application (Art. 63(1)),\n</p>\n<dl><dd>\" nothing (...) shall limit the right of a Contracting State to extend the term of a European patent, or to grant corresponding protection which follows immediately on expiry of the term of the patent, under the same conditions as those applying to national patents: (...)</dd>\n<dd>(b) if the subject-matter of the European patent is a product or a process of manufacturing a product or a use of a product which has to undergo an administrative authorisation procedure required by law before it can be put on the market in that State. \" <sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup></dd></dl>\n<p>This constituted the first revision of the European Patent Convention since its signature in 1973.\n</p><p>The paediatric extension is based primarily upon:\n</p>\n<ul><li>Regulation 1901/2006 of 12 December 2006 on medicinal products for paediatric use and amending Regulation 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 <sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup></li>\n<li>Regulation 1902/2006 of 20 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use<sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup></li></ul>\n<h2><span class=\"mw-headline\" id=\"Determination_of_term\">Determination of term</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Supplementary_protection_certificate&amp;action=edit&amp;section=3\" title=\"Edit section: Determination of term\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The term of an SPC depends on the date of issuance of the first marketing authorization (MA) within the <a href=\"/wiki/European_Economic_Area\" title=\"European Economic Area\">EEA</a> and can be determined by the equation:\n</p>\n<dl><dd>Term = <b>date of 1st MA in the EEA &#8722; date of filing of corresponding patent &#8722; 5 years</b></dd></dl>\n<p>Under normal circumstances, this means the following.\n</p>\n<ul><li>No SPC term is available if less than 5 years have elapsed between the date of filing of the corresponding patent and the date of issuance of the first MA in the EEA.</li>\n<li>If the first MA is issued more than five years but less than ten years after the filing date of the corresponding patent, an SPC is granted for a term corresponding to the period elapsed between the five-year point and the MA issuance date.</li>\n<li>If the first MA is issued more than ten years after the filing date of the corresponding patent, an SPC is granted for a five-year term.</li></ul>\n<p>There have been very few cases where there was any controversy over the precise date of the 1st MA in the EEA. The H\u00e4ssle AB case (ECJ case C-127/00<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup>) was one of that small number. In that case, the ECJ ruled that the decisive date for SPC purposes is the date of an authorisation from a regulatory body tasked with assessing safety and efficacy, and not the date of a subsequent authorisation that may be required under national pricing or reimbursement provisions.\n</p><p>So-called \"centralised\" (<a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> / European Commission) MAs were introduced by Regulation 2309/93<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup> and became available in January 1995 (i.e. some 2 years after the introduction of the original SPC legislation for medicinal products). The introduction of these authorisations added a new layer of complexity to the issue of determination of the date of a MA. This is because there are two dates associated with \"centralised\" authorisations, namely: (1) the date of the European Commission's decision to issue an authorisation; and (2) the date of notification of that decision to the MA applicant.  Date (2) is usually a few days (e.g. 2 to 4 days) later than date (1).  Although the standard practice of many national patent offices seems to be to calculate SPC term based upon date (1), an October 2011 article in Scrip Regulatory Affairs by Mike Snodin<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup> argues that this standard practice is incorrect and that date (2) should be used instead (with the result that some products may be entitled to a slightly longer SPC term than previously thought). Paramount amongst the reasons for preferring date (2) to date (1) is that a \"centralised\" authorisation does not become effective until it is notified to the MA applicant.\n</p><p>The UK Intellectual Property Office has now accepted Snodin's arguments on this point and has changed its standard practice regarding the calculation of SPC term.<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup>  It remains to be seen whether any other national offices will follow suit. However, inspection of Belgian SPC certificates for products authorised via the \"centralised\" procedure reveals that at least the patent office in Belgium already appears to base calculations of SPC term upon date (2). Thus, there are divergent practices across different territories within Europe with regard to the selection of a date for a \"centralised\" MA, with Belgium and the UK IPO being in the minority. If the issue were ever to be debated in a national court, this fact that there are divergent practices across different territories could provide basis for such a court to seek an authoratitive ruling from the ECJ in relation to which of dates (1) and (2) should be used for SPCs. This is because, as European Commission legislation, the Regulations governing SPCs should be interpreted consistently across all member states of the EU.\n</p><p>An MA in <a href=\"/wiki/Switzerland\" title=\"Switzerland\">Switzerland</a> was also considered as being a first MA for the calculation of the SPC duration, even though Switzerland is not part of the <a href=\"/wiki/European_Economic_Area\" title=\"European Economic Area\">European Economic Area</a> (EEA). This is because such a MA was automatically effective in <a href=\"/wiki/Liechtenstein\" title=\"Liechtenstein\">Liechtenstein</a>, which is a member of the EEA (since 1 May 1995). This was decided by the <a href=\"/wiki/European_Court_of_Justice\" title=\"European Court of Justice\">European Court of Justice</a> (ECJ) in joined cases <i>Novartis et al. v. Comptroller-General</i> and <i>Minist\u00e8re de l'Economie v. Millennium Pharmaceuticals</i>.<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup><sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup>  The same point was also confirmed in case C-617/12 (<i>AstraZeneca AB v Comptroller General of Patents, Designs and Trade Marks</i>),<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup> in a case where the data that persuaded Swissmedic to grant the (earlier) Swiss MA was held by the European Medicines Agency to not be complete or persuasive enough to justify the grant of a MA under EU legislation (Directive 2001/83/EC).\nHowever, as answer to the decision of the ECJ the contract between Switzerland and Liechtenstein was amended. Since 1 July 2005 the automatic effect of a Swiss MA in Liechtenstein is abolished. The recognition is now delayed by a time period, which is normally 12 months.\n</p>\n<h3><span class=\"mw-headline\" id=\"Paediatric_extension\">Paediatric extension</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Supplementary_protection_certificate&amp;action=edit&amp;section=4\" title=\"Edit section: Paediatric extension\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Article 36 of Regulation 1901/2006 provides for a 6-month extension to SPC term. The extension is available only under certain conditions, the most notable being the requirement for the submission of a new MA application containing data from all trials conducted in accordance with an agreed Paediatric Investigation Plan (PIP).\n</p><p>Consequences of the 6-month SPC extension include:\n</p>\n<ul><li>the maximum term of an SPC can now be up to 5.5 years; and</li>\n<li>the maximum duration of market exclusivity (patent + SPC) can now be up to at least 15.5 years.</li></ul>\n<p>An extension of an SPC can only be awarded if there is an SPC to extend.  As an unextended SPC only has a positive term if more than 5 years have elapsed between patent filing and MA issuance, this leads to the following two questions.\n</p><p>(1) Is an SPC available if less than 5 years and 1 day have elapsed between filing of the corresponding patent and issuance of the first MA in the EEA?\n</p><p>(2) If the answer to (1) is yes, what term should be awarded to the (unextended) SPC?\n</p><p>A July 2007 paper by Snodin and Miles,<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup> put forward three possible answers to this combination of two questions.\n</p><p>If the answer to question (1) is no, then it is not relevant to consider question (2). This corresponds to \"Model B\" of the 2007 Snodin and Miles paper, and produces a curious situation where longer marketing exclusivity can be obtained if the issuance of the first MA in the EEA is delayed (to at least 5 years and 1-day from filing of the corresponding patent).\n</p><p>If the answer to question (1) is yes, then question (2) becomes relevant. This question can be answered in two ways, corresponding to either \"Model A\" or \"Model C\" of the 2007 Snodin and Miles paper.\n</p><p>Model A assumes that SPC term can validly be either zero or negative if 5 years or less have elapsed from filing of the corresponding patent to issuance of the first MA in the EEA. In this event, a positive (and non-zero) SPC term is obtained (after extension) if the time from patent filing to MA issuance is more than 4.5 years.\n</p><p>Model C assumes that all term calculations that provide a negative answer are 'rounded up' to zero. This has the consequence of providing a minimum of 6 months of SPC term, irrespective of how little time has elapsed from patent filing to MA issuance.\n</p><p>Subsequent to the publication of the Snodin and Miles article, Merck &amp; Co. filed SPC applications for the product <a href=\"/wiki/Sitagliptin\" title=\"Sitagliptin\">sitagliptin</a>. For example, from mid-August to mid-September 2007, Merck &amp; Co. filed SPC applications in various countries, including the UK,<sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup> Ireland,<sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup> the Netherlands<sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup> and Italy.<sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup> These SPC applications provided an early opportunity for Models A to C to be tested in practice. Curiously, the patent offices of various EU member states did not reach any consensus on which model is correct. For example, the Netherlands<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup> and the UK<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup> favoured Model A, Germany,<sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup> Portugal and Slovenia favoured Model B and Greece<sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup> favoured Model C.\n</p><p>In connection with an appeal against refusal of the SPC application in Germany, and in view of the different stances taken by different national patent offices, the <a href=\"/wiki/German_Federal_Court_of_Justice\" class=\"mw-redirect\" title=\"German Federal Court of Justice\">German Federal Court of Justice</a> (<i>Bundesgerichtshof</i>) sought clarification of the law from the Court of Justice of the EU (in case C-125/10).\n</p><p>The decision of the Court of Justice, delivered on 8 December 2011,<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup> essentially agreed with Model A of the 2007 Snodin and Miles paper. Thus, useful (extended) supplementary protection can now be obtained so long as at least 4 years, 6 months and one day has elapsed from the date of patent filing to the date of the first MA for the product in the EEA.\n</p>\n<h2><span class=\"mw-headline\" id=\"Case_law\">Case law</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Supplementary_protection_certificate&amp;action=edit&amp;section=5\" title=\"Edit section: Case law\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>ECJ cases C-195/09 and C-427/09 effectively ruled that SPCs for medicaments (human or veterinary) are only available for those \"products\" that:\n</p><p>(a) are protected by a patent;\n</p><p>(b) have been subject to an administrative authorisation procedure; and\n</p><p>(c) have not been placed on the market anywhere in the <a href=\"/wiki/European_Economic_Area\" title=\"European Economic Area\">EEA</a> as a medicinal product prior to being subject to safety and efficacy testing and a regulatory review.\n</p><p>Until recently, decisions C-195/09 and C-427/09 could have been interpreted as ruling out the possibility of SPC protection for all \"products\" previously included in medicinal products that were marketed prior to the date(s) of the Marketing Authorisation(s) (MA(s)) specified in the SPC application. This is because the ECJ's rulings in C-195/09 and C-427/09 were based in part upon a desire to ensure that national patent offices are not required to assess whether an earlier MA was compliant with the standards for testing of safety and efficacy that were introduced in the 1970s (meaning that all prior MAs, whether or not compliant with those standards, should be treated equally under the SPC legislation).\n</p><p>However, the decision in Neurim Pharmaceuticals (C-130/11) has cast doubt upon this interpretation. In C-130/11, the ECJ held that an SPC can be granted regardless of the prior marketing of earlier (veterinary) medicinal products containing the \"product\" in question. Thus, cases C-195/09 and C-427/09 (which, in common with C-130/11, related to SPC applications based upon newly patented uses for old \"products\") could perhaps now be viewed as being of relevance only to those \"products\" that were marketed before being subject to a regulatory review. However, this might necessitate patent offices making a determination of whether prior MAs are compliant with current standards (i.e. whether the \"product\" had been subject to safety and efficacy testing prior to being granted an MA). As this is precisely the kind of determination that the ECJ had previously been keen for patent offices to avoid, further references to the ECJ may be necessary to clarify precisely which \"products\" fall within the scope of the SPC legislation and which do not.\n</p><p>With respect to (a) above, the question of how to determine whether a \"product\" is protected by a patent is the subject of ongoing controversy. Cases such as C-322/10 and C-422/10 have indicated that the \"product\" needs to be \"specified [or identified] in the wording of the claims\". However, the precise meaning of this test is yet to be clarified.\n</p><p>Further, although the SPC legislation mentions only Directives 2001/83/EC and 2001/82/EC as the \"administrative authorisation procedure\" for human or veterinary medicaments, SPCs are known to have been granted when MAs have not been obtained via those procedures (but instead via procedures that involve a similar level of safety and efficacy testing)<a rel=\"nofollow\" class=\"external autonumber\" href=\"http://thespcblog.blogspot.com/2010/03/spc-on-basis-of-ma-for-active.html\">[1]</a>.\n</p>\n<h2><span class=\"mw-headline\" id=\"Statistics\">Statistics</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Supplementary_protection_certificate&amp;action=edit&amp;section=6\" title=\"Edit section: Statistics\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>According to research, more than 8,000 SPCs for medicinal and plant protection products have been filed in Europe between 1991 and 2003.<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Supplementary_protection_certificate&amp;action=edit&amp;section=7\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Orphan_drug\" title=\"Orphan drug\">Orphan drug</a></li>\n<li><a href=\"/wiki/European_Federation_of_Pharmaceutical_Industries_and_Associations\" title=\"European Federation of Pharmaceutical Industries and Associations\">European Federation of Pharmaceutical Industries and Associations</a> (EFPIA)</li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Supplementary_protection_certificate&amp;action=edit&amp;section=8\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\">\"<i>... Whereas at the moment the period that elapses between the filing of an application for a patent for a new medicinal product and authorization to place the medicinal product on the market makes the period of effective protection under the patent insufficient to cover the investment put into the research ...</i>\" in <a rel=\"nofollow\" class=\"external text\" href=\"http://europa.eu/eur-lex/lex/LexUriServ/LexUriServ.do?uri=CELEX:31992R1768:EN:HTML\">Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products</a></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf\">Regulation (EC) No 1901/2006 on medicinal products for paediatric use</a></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://curia.europa.eu/jurisp/cgi-bin/form.pl?lang=en&amp;newform=newform&amp;Submit=Submit&amp;alljur=alljur&amp;jurcdj=jurcdj&amp;jurtpi=jurtpi&amp;jurtfp=jurtfp&amp;alldocrec=alldocrec&amp;docj=docj&amp;docor=docor&amp;docop=docop&amp;docav=docav&amp;docsom=docsom&amp;docinf=docinf&amp;alldocnorec=alldocnorec&amp;docnoj=docnoj&amp;docnoor=docnoor&amp;typeord=ALL&amp;docnodecision=docnodecision&amp;allcommjo=allcommjo&amp;affint=affint&amp;affclose=affclose&amp;numaff=C-392%2F97&amp;ddatefs=&amp;mdatefs=&amp;ydatefs=&amp;ddatefe=&amp;mdatefe=&amp;ydatefe=&amp;nomusuel=&amp;domaine=&amp;mots=&amp;resmax=100\">Farmitalia Carlo Erba Srl's SPC Application (Case C-392/97)</a></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://europa.eu/eur-lex/lex/LexUriServ/LexUriServ.do?uri=CELEX:31992R1768:EN:HTML\">Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products</a></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://europa.eu/eur-lex/lex/LexUriServ/LexUriServ.do?uri=CELEX:31996R1610:EN:HTML\">Regulation (EC) No 1610/96 of the European Parliament and of the Council of 23 July 1996 concerning the creation of a supplementary protection certificate for plant protection products</a></span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:152:0001:0010:en:PDF\">Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version)</a></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.epo.org/law-practice/legal-texts/html/epc/2013/e/ar63.html\">Article 63</a> <a href=\"/wiki/European_Patent_Convention\" title=\"European Patent Convention\">EPC</a></span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf\">Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004</a></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2006_1902/reg_2006_1902_en.pdf\">Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use</a></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://curia.europa.eu/jurisp/cgi-bin/form.pl?lang=en&amp;newform=newform&amp;Submit=Submit&amp;alljur=alljur&amp;jurcdj=jurcdj&amp;jurtpi=jurtpi&amp;jurtfp=jurtfp&amp;alldocrec=alldocrec&amp;docj=docj&amp;docor=docor&amp;docdecision=docdecision&amp;docop=docop&amp;docppoag=docppoag&amp;docav=docav&amp;docsom=docsom&amp;docinf=docinf&amp;alldocnorec=alldocnorec&amp;docnoj=docnoj&amp;docnoor=docnoor&amp;radtypeord=on&amp;typeord=ALL&amp;docnodecision=docnodecision&amp;allcommjo=allcommjo&amp;affint=affint&amp;affclose=affclose&amp;numaff=C-127%2F00&amp;ddatefs=&amp;mdatefs=&amp;ydatefs=&amp;ddatefe=&amp;mdatefe=&amp;ydatefe=&amp;nomusuel=&amp;domaine=&amp;mots=&amp;resmax=100\">Case C-127/00</a></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://ec.europa.eu/health/files/eudralex/vol-1/reg_1993_2309/reg_1993_2309_en.pdf\">Regulation 2309/93</a></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://thespcblog.blogspot.com/2011/10/every-day-counts-but-how-do-we-count.html\">Mike Snodin October 2011 article</a></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ipo.gov.uk/pro-types/pro-patent/p-law/p-pn/p-pn-spcduration.htm\">UK IPO Practice Notice</a> <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20131213173040/http://www.ipo.gov.uk/pro-types/pro-patent/p-law/p-pn/p-pn-spcduration.htm\">Archived</a> 13 December 2013 at the <a href=\"/wiki/Wayback_Machine\" title=\"Wayback Machine\">Wayback Machine</a>.</span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://eur-lex.europa.eu/pri/en/oj/dat/2003/c_158/c_15820030705en00170017.pdf\">Case C-207/03</a></span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://eur-lex.europa.eu/pri/en/oj/dat/2003/c_200/c_20020030823en00120012.pdf\">Case C-252/03</a></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://curia.europa.eu/juris/document/document.jsf?text=&amp;docid=144849&amp;pageIndex=0&amp;doclang=EN&amp;mode=lst&amp;dir=&amp;occ=first&amp;part=1&amp;cid=288106\">Case C-617/12</a></span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.potterclarkson.com/pdfs/newsletters/making-the-most-of-paediatric-spc-extensions.pdf\">Snodin and Miles <i>RAJ Pharma</i> 18(7), 459 (2007)</a> <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20120127093250/http://www.potterclarkson.com/pdfs/newsletters/making-the-most-of-paediatric-spc-extensions.pdf\">Archived</a> 27 January 2012 at the <a href=\"/wiki/Wayback_Machine\" title=\"Wayback Machine\">Wayback Machine</a>.</span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ipo.gov.uk/p-find-spc-byspc-results.htm?number=SPC/GB07/046\">Register Extract for UK SPC for sitagliptin phosphate monohydrate</a></span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.patentsoffice.ie/eregister/register/SPRegister.aspx?idappli=2007/029\">Register Extract for IE SPC for sitagliptin</a></span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://register.octrooicentrum.nl/register/gegevens/CERT/300287\">Register Extract for NL SPC for sitagliptin</a></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.uibm.gov.it/uibm/dati/Codice.aspx?load=info&amp;id=1541780&amp;table=CCP\">Register Extract for IT SPC for sitagliptin</a></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://register.octrooicentrum.nl/register/gegevens/CERT/300287\">Register Extract for NL SPC for sitagliptin, showing an SPC expiry date earlier than the expiry date of the basic patent</a></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ipo.gov.uk/pro-types/pro-patent/pro-p-os/o10808.pdf\">UKIPO decision granting negative term SPC</a></span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://thespcblog.blogspot.com/2010/04/full-translation-of-german-sitagliptin.html\">Translation of referral from BGH to the CJEU in Merck's appeal against refusal of sitagliptin SPC application in Germany</a></span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://thespcblog.blogspot.com/2009/02/sitagliptin-nl-negative-term.html\">Commentary on SPC applications for sitagliptin</a></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://curia.europa.eu/juris/liste.jsf?language=en&amp;jur=C,T,F&amp;num=C-125/10&amp;td=ALL\">C-125/10 \u2013 Merck Sharp &amp; Dohme, Judgment of the Court (Second Chamber) of 8 December 2011</a></span>\n</li>\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\">EurActiv, <a rel=\"nofollow\" class=\"external text\" href=\"http://www.euractiv.com/en/health/eu-ruling-extension-pharma-patents-harder/article-154974\"><i>EU ruling makes extension of pharma patents harder</i></a>, 5 May 2006</span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Supplementary_protection_certificate&amp;action=edit&amp;section=9\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.patent.gov.uk/patent/info/spctext.pdf\">Supplementary Protection Certificates for Medicinal Products and Plant Protection Products \u2013 A Guide for Applicants</a> (PDF file 120Kb), by the <a href=\"/wiki/United_Kingdom_Patent_Office\" class=\"mw-redirect\" title=\"United Kingdom Patent Office\">UK Patent Office</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://thespcblog.blogspot.com/\">The SPC Blog</a>, blog relating to supplementary protection certificates (SPCs)</li></ul>\n<h3><span class=\"mw-headline\" id=\"Search\">Search</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Supplementary_protection_certificate&amp;action=edit&amp;section=10\" title=\"Edit section: Search\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ipo.gov.uk/p-find-spc.htm\">Supplementary Protection Certificate Search</a> at the UK Intellectual Property Office</li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw1265\nCached time: 20180909110602\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.164 seconds\nReal time usage: 0.208 seconds\nPreprocessor visited node count: 752/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 14870/2097152 bytes\nTemplate argument size: 431/2097152 bytes\nHighest expansion depth: 12/40\nExpensive parser function count: 2/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 13727/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.025/10.000 seconds\nLua memory usage: 1.29 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  149.359      1 -total\n 32.18%   48.058      1 Template:Reflist\n 27.50%   41.076      1 Template:EngvarB\n 15.50%   23.148      1 Template:Intellectual_property\n 13.82%   20.644      2 Template:DMCA\n 10.95%   16.350      2 Template:Webarchive\n  9.93%   14.831      2 Template:Dated_maintenance_category\n  8.28%   12.369      1 Template:European_patent_law\n  6.67%    9.967      1 Template:Sidebar\n  6.65%    9.931      2 Template:FULLROOTPAGENAME\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:2202344-0!canonical and timestamp 20180909110602 and revision id 844871433\n -->\n</div>"},"langlinks":[{"lang":"de","url":"https://de.wikipedia.org/wiki/Erg%C3%A4nzendes_Schutzzertifikat","langname":"German","autonym":"Deutsch","*":"Erg\u00e4nzendes Schutzzertifikat"},{"lang":"fr","url":"https://fr.wikipedia.org/wiki/Certificat_compl%C3%A9mentaire_de_protection","langname":"French","autonym":"fran\u00e7ais","*":"Certificat compl\u00e9mentaire de protection"},{"lang":"is","url":"https://is.wikipedia.org/wiki/Vottor%C3%B0_um_vi%C3%B0b%C3%B3tarvernd","langname":"Icelandic","autonym":"\u00edslenska","*":"Vottor\u00f0 um vi\u00f0b\u00f3tarvernd"},{"lang":"it","url":"https://it.wikipedia.org/wiki/Certificato_di_protezione_complementare","langname":"Italian","autonym":"italiano","*":"Certificato di protezione complementare"}],"categories":[{"sortkey":"","hidden":"","*":"Webarchive_template_wayback_links"},{"sortkey":"","hidden":"","*":"EngvarB_from_May_2013"},{"sortkey":"","hidden":"","*":"Use_dmy_dates_from_May_2013"},{"sortkey":"","*":"Intellectual_property_law"},{"sortkey":"","*":"Patent_law_of_the_European_Union"}],"links":[{"ns":14,"exists":"","*":"Category:EngvarB from May 2013"},{"ns":14,"exists":"","*":"Category:Use dmy dates from May 2013"},{"ns":10,"exists":"","*":"Template:Intellectual property"},{"ns":10,"exists":"","*":"Template:European patent law"},{"ns":0,"exists":"","*":"Abandonware"},{"ns":0,"exists":"","*":"Anti-copyright"},{"ns":0,"exists":"","*":"Authors' rights"},{"ns":0,"exists":"","*":"Bioprospecting"},{"ns":0,"exists":"","*":"Brussels Regime"},{"ns":0,"exists":"","*":"Copyright"},{"ns":0,"exists":"","*":"Council of the European Union"},{"ns":0,"exists":"","*":"Cross-border injunction"},{"ns":0,"exists":"","*":"Cultural appropriation"},{"ns":0,"exists":"","*":"Database right"},{"ns":0,"exists":"","*":"Directive on the patentability of biotechnological inventions"},{"ns":0,"exists":"","*":"Eurasian Patent Convention"},{"ns":0,"exists":"","*":"Eurasian Patent Office"},{"ns":0,"exists":"","*":"Eurasian Patent Organization"},{"ns":0,"exists":"","*":"European Community"},{"ns":0,"exists":"","*":"European Court of Justice"},{"ns":0,"exists":"","*":"European Economic Area"},{"ns":0,"exists":"","*":"European Federation of Pharmaceutical Industries and Associations"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"European Parliament"},{"ns":0,"exists":"","*":"European Patent Convention"},{"ns":0,"exists":"","*":"European Patent Litigation Agreement"},{"ns":0,"exists":"","*":"European Patent Office"},{"ns":0,"exists":"","*":"European Patent Organisation"},{"ns":0,"exists":"","*":"European Union"},{"ns":0,"exists":"","*":"European Union regulation"},{"ns":0,"exists":"","*":"European patent law"},{"ns":0,"exists":"","*":"Fair dealing"},{"ns":0,"exists":"","*":"Fair use"},{"ns":0,"exists":"","*":"Geographical indication"},{"ns":0,"exists":"","*":"German Federal Court of Justice"},{"ns":0,"exists":"","*":"Herbicide"},{"ns":0,"exists":"","*":"Indigenous intellectual property"},{"ns":0,"exists":"","*":"Industrial design right"},{"ns":0,"exists":"","*":"Insecticide"},{"ns":0,"exists":"","*":"Integrated circuit layout design protection"},{"ns":0,"exists":"","*":"Intellectual property"},{"ns":0,"exists":"","*":"Intellectual rights"},{"ns":0,"exists":"","*":"Liechtenstein"},{"ns":0,"exists":"","*":"Limitations and exceptions to copyright"},{"ns":0,"exists":"","*":"London Agreement (2000)"},{"ns":0,"exists":"","*":"Moral rights"},{"ns":0,"exists":"","*":"Orphan drug"},{"ns":0,"exists":"","*":"Orphan works"},{"ns":0,"exists":"","*":"Outline of intellectual property"},{"ns":0,"exists":"","*":"Outline of patents"},{"ns":0,"exists":"","*":"Paraphrasing of copyrighted material"},{"ns":0,"exists":"","*":"Patent"},{"ns":0,"exists":"","*":"Patent law of the European Union"},{"ns":0,"exists":"","*":"Patent troll"},{"ns":0,"exists":"","*":"Plant breeders' rights"},{"ns":0,"exists":"","*":"Property"},{"ns":0,"exists":"","*":"Property law"},{"ns":0,"exists":"","*":"Public domain"},{"ns":0,"exists":"","*":"Related rights"},{"ns":0,"exists":"","*":"Right to quote"},{"ns":0,"exists":"","*":"Sitagliptin"},{"ns":0,"exists":"","*":"Sui generis"},{"ns":0,"exists":"","*":"Switzerland"},{"ns":0,"exists":"","*":"Term of patent"},{"ns":0,"exists":"","*":"Trade dress"},{"ns":0,"exists":"","*":"Trade secret"},{"ns":0,"exists":"","*":"Trademark"},{"ns":0,"exists":"","*":"Unified Patent Court"},{"ns":0,"exists":"","*":"Unitary patent"},{"ns":0,"exists":"","*":"United Kingdom Patent Office"},{"ns":0,"exists":"","*":"Utility model"},{"ns":0,"exists":"","*":"Wayback Machine"},{"ns":11,"exists":"","*":"Template talk:European patent law"},{"ns":11,"exists":"","*":"Template talk:Intellectual property"}],"templates":[{"ns":10,"exists":"","*":"Template:EngvarB"},{"ns":10,"exists":"","*":"Template:DMCA"},{"ns":10,"exists":"","*":"Template:Dated maintenance category"},{"ns":10,"exists":"","*":"Template:FULLROOTPAGENAME"},{"ns":10,"exists":"","*":"Template:Ns has subpages"},{"ns":10,"exists":"","*":"Template:Use dmy dates"},{"ns":10,"exists":"","*":"Template:Intellectual property"},{"ns":10,"exists":"","*":"Template:Law sidebar style"},{"ns":10,"exists":"","*":"Template:Startflatlist"},{"ns":10,"exists":"","*":"Template:Flatlist"},{"ns":10,"exists":"","*":"Template:Endflatlist"},{"ns":10,"exists":"","*":"Template:European patent law"},{"ns":10,"exists":"","*":"Template:Sidebar"},{"ns":10,"exists":"","*":"Template:Longlink"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:EPC Article"},{"ns":10,"exists":"","*":"Template:Webarchive"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Ns has subpages"},{"ns":828,"exists":"","*":"Module:Sidebar"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:Webarchive"},{"ns":828,"exists":"","*":"Module:Webarchive/data"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":[],"externallinks":["http://europa.eu/eur-lex/lex/LexUriServ/LexUriServ.do?uri=CELEX:31992R1768:EN:HTML","http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf","http://curia.europa.eu/jurisp/cgi-bin/form.pl?lang=en&newform=newform&Submit=Submit&alljur=alljur&jurcdj=jurcdj&jurtpi=jurtpi&jurtfp=jurtfp&alldocrec=alldocrec&docj=docj&docor=docor&docop=docop&docav=docav&docsom=docsom&docinf=docinf&alldocnorec=alldocnorec&docnoj=docnoj&docnoor=docnoor&typeord=ALL&docnodecision=docnodecision&allcommjo=allcommjo&affint=affint&affclose=affclose&numaff=C-392/97&ddatefs=&mdatefs=&ydatefs=&ddatefe=&mdatefe=&ydatefe=&nomusuel=&domaine=&mots=&resmax=100","http://europa.eu/eur-lex/lex/LexUriServ/LexUriServ.do?uri=CELEX:31996R1610:EN:HTML","http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:152:0001:0010:en:PDF","https://www.epo.org/law-practice/legal-texts/html/epc/2013/e/ar63.html","http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2006_1902/reg_2006_1902_en.pdf","http://curia.europa.eu/jurisp/cgi-bin/form.pl?lang=en&newform=newform&Submit=Submit&alljur=alljur&jurcdj=jurcdj&jurtpi=jurtpi&jurtfp=jurtfp&alldocrec=alldocrec&docj=docj&docor=docor&docdecision=docdecision&docop=docop&docppoag=docppoag&docav=docav&docsom=docsom&docinf=docinf&alldocnorec=alldocnorec&docnoj=docnoj&docnoor=docnoor&radtypeord=on&typeord=ALL&docnodecision=docnodecision&allcommjo=allcommjo&affint=affint&affclose=affclose&numaff=C-127/00&ddatefs=&mdatefs=&ydatefs=&ddatefe=&mdatefe=&ydatefe=&nomusuel=&domaine=&mots=&resmax=100","http://ec.europa.eu/health/files/eudralex/vol-1/reg_1993_2309/reg_1993_2309_en.pdf","http://thespcblog.blogspot.com/2011/10/every-day-counts-but-how-do-we-count.html","http://www.ipo.gov.uk/pro-types/pro-patent/p-law/p-pn/p-pn-spcduration.htm","https://web.archive.org/web/20131213173040/http://www.ipo.gov.uk/pro-types/pro-patent/p-law/p-pn/p-pn-spcduration.htm","http://eur-lex.europa.eu/pri/en/oj/dat/2003/c_158/c_15820030705en00170017.pdf","http://eur-lex.europa.eu/pri/en/oj/dat/2003/c_200/c_20020030823en00120012.pdf","http://curia.europa.eu/juris/document/document.jsf?text=&docid=144849&pageIndex=0&doclang=EN&mode=lst&dir=&occ=first&part=1&cid=288106","http://www.potterclarkson.com/pdfs/newsletters/making-the-most-of-paediatric-spc-extensions.pdf","https://web.archive.org/web/20120127093250/http://www.potterclarkson.com/pdfs/newsletters/making-the-most-of-paediatric-spc-extensions.pdf","http://www.ipo.gov.uk/p-find-spc-byspc-results.htm?number=SPC/GB07/046","http://www.patentsoffice.ie/eregister/register/SPRegister.aspx?idappli=2007/029","http://register.octrooicentrum.nl/register/gegevens/CERT/300287","http://www.uibm.gov.it/uibm/dati/Codice.aspx?load=info&id=1541780&table=CCP","http://www.ipo.gov.uk/pro-types/pro-patent/pro-p-os/o10808.pdf","http://thespcblog.blogspot.com/2010/04/full-translation-of-german-sitagliptin.html","http://thespcblog.blogspot.com/2009/02/sitagliptin-nl-negative-term.html","http://curia.europa.eu/juris/liste.jsf?language=en&jur=C,T,F&num=C-125/10&td=ALL","http://www.euractiv.com/en/health/eu-ruling-extension-pharma-patents-harder/article-154974","http://thespcblog.blogspot.com/2010/03/spc-on-basis-of-ma-for-active.html","http://www.patent.gov.uk/patent/info/spctext.pdf","http://thespcblog.blogspot.com/","http://www.ipo.gov.uk/p-find-spc.htm"],"sections":[{"toclevel":1,"level":"2","line":"Scope","number":"1","index":"1","fromtitle":"Supplementary_protection_certificate","byteoffset":3308,"anchor":"Scope"},{"toclevel":1,"level":"2","line":"Legal basis","number":"2","index":"2","fromtitle":"Supplementary_protection_certificate","byteoffset":4937,"anchor":"Legal_basis"},{"toclevel":1,"level":"2","line":"Determination of term","number":"3","index":"3","fromtitle":"Supplementary_protection_certificate","byteoffset":9019,"anchor":"Determination_of_term"},{"toclevel":2,"level":"3","line":"Paediatric extension","number":"3.1","index":"4","fromtitle":"Supplementary_protection_certificate","byteoffset":15317,"anchor":"Paediatric_extension"},{"toclevel":1,"level":"2","line":"Case law","number":"4","index":"5","fromtitle":"Supplementary_protection_certificate","byteoffset":20661,"anchor":"Case_law"},{"toclevel":1,"level":"2","line":"Statistics","number":"5","index":"6","fromtitle":"Supplementary_protection_certificate","byteoffset":23660,"anchor":"Statistics"},{"toclevel":1,"level":"2","line":"See also","number":"6","index":"7","fromtitle":"Supplementary_protection_certificate","byteoffset":23995,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"7","index":"8","fromtitle":"Supplementary_protection_certificate","byteoffset":24109,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"8","index":"9","fromtitle":"Supplementary_protection_certificate","byteoffset":24144,"anchor":"External_links"},{"toclevel":2,"level":"3","line":"Search","number":"8.1","index":"10","fromtitle":"Supplementary_protection_certificate","byteoffset":24522,"anchor":"Search"}],"parsewarnings":[],"displaytitle":"Supplementary protection certificate","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q456854"}]}}